九洲药业(603456) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 reached ¥1,418,207,438.23, representing a year-on-year increase of 24.83%[4] - The net profit attributable to shareholders for Q3 2022 was ¥275,166,576.91, up 38.77% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥294,301,623.25, reflecting a 54.11% increase year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.33, an increase of 37.50% compared to the same period last year[4] - The diluted earnings per share for Q3 2022 was also ¥0.33, reflecting a 37.50% increase year-on-year[4] - The company achieved a net profit of ¥743.23 million for the first three quarters of 2022, a growth of 57.09% year-on-year[6] - The total operating revenue for the first three quarters of 2022 reached ¥4,372,695,484.55, a significant increase of 45.5% compared to ¥3,004,229,474.76 in the same period of 2021[21] - The total profit for Q3 2022 was CNY 871,579,890.61, an increase of 60.1% from CNY 544,184,530.47 in Q3 2021[22] - The company’s operating profit for Q3 2022 was CNY 873,921,630.43, up from CNY 549,152,950.95 in Q3 2021, reflecting a growth of 59.0%[22] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥1,236,399,937.86, showing a significant increase of 191.42%[4] - As of September 30, 2022, cash and cash equivalents amounted to 1,495,710,632.14 RMB, an increase from 1,120,801,411.69 RMB at the end of 2021[17] - The cash and cash equivalents at the end of Q3 2022 amounted to CNY 1,077,953,018.45, up from CNY 858,721,339.25 at the end of Q3 2021, showing an increase of 25.6%[25] - The company's total assets as of the end of Q3 2022 amounted to ¥7,839,931,627.65, an increase of 11.36% from the end of the previous year[5] - The total current assets as of September 30, 2022, were 4,179,264,243.64 RMB, compared to 3,771,883,813.73 RMB at the end of 2021[17] - The company's accounts receivable decreased to 631,823,867.17 RMB from 767,032,258.42 RMB year-over-year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,481[10] - Zhejiang Zhongbei Jiuzhou Group Co., Ltd. holds 283,518,812 shares, accounting for 33.98% of total shares[10] - The top ten unrestricted shareholders include China Industrial Bank Co., Ltd. with 40,737,316 shares (4.88%) and Taizhou GeDe Industrial Co., Ltd. with 40,585,680 shares (4.86%)[11] Business Development - The strong performance was primarily driven by the growth in the CDMO business, supported by enhanced customer engagement and operational efficiency[6] - The company aims to achieve a one-stop capability from CMC research and development to commercial production in the CDMO industry[15] - The company signed an equity acquisition agreement with Sandos (China) Pharmaceutical Co., Ltd. to enhance its CDMO formulation business capabilities, with a fundraising amount of 185 million RMB[14] Expenses and Liabilities - Total operating costs for the first three quarters of 2022 were ¥3,439,860,576.73, up 39.0% from ¥2,472,370,398.44 in the previous year[21] - Research and development expenses increased to ¥227,413,281.50, representing an 86.5% rise from ¥122,104,944.00 in the prior year[21] - The total liabilities of the company were ¥2,633,390,645.01, up from ¥2,463,293,930.93, indicating a rise of 6.9%[19] - The equity attributable to shareholders reached ¥5,128,440,403.51, compared to ¥4,577,129,753.17, marking an increase of 12.0%[19] Tax and Investment Income - The company reported a tax expense of CNY 130,100,644.37 for Q3 2022, compared to CNY 70,801,890.24 in Q3 2021, which is an increase of 83.8%[22] - The company reported a net profit of ¥20,282,370.13 from investment income, down 54.8% from ¥44,792,103.57 in the previous year[21]